Given their antitumor effects, somatostatin analogs such as octreotide and lanreotide (both are potent SSTR2 agonists but notably spare SSTR1) have been approved to treat gastroenteropancreatic NE tumors and carcinoid syndrome (57, 58). The gene discussed is SSTR2; the disease is carcinoid syndrome.